STUDY OBJECTIVES: In schizophrenia there is a dramatic reduction of sleep spindles that predicts deficient sleep-dependent memory consolidation. Eszopiclone (Lunesta), a non-benzodiazepine hypnotic, acts on γ-aminobutyric acid (GABA) neurons in the thalamic reticular nucleus where spindles are generated. We investigated whether eszopiclone could increase spindles and thereby improve memory consolidation in schizophrenia. DESIGN: In a double-blind design, patients were randomly assigned to receive either placebo or 3 mg of eszopiclone. Patients completed Baseline and Treatment visits, each consisting of two consecutive nights of polysomnography. On the second night of each visit, patients were trained on the motor sequence task (MST) at bedtime and tested the following morning. SETTING: Academic research center. PARTICIPANTS: Twenty-one chronic, medicated schizophrenia outpatients. MEASUREMENTS AND RESULTS: We compared the effects of two nights of eszopiclone vs. placebo on stage 2 sleep spindles and overnight changes in MST performance. Eszopiclone increased the number and density of spindles over baseline levels significantly more than placebo, but did not significantly enhance overnight MST improvement. In the combined eszopiclone and placebo groups, spindle number and density predicted overnight MST improvement. CONCLUSION:Eszopiclone significantly increased sleep spindles, which correlated with overnight motor sequence task improvement. These findings provide partial support for the hypothesis that the spindle deficit in schizophrenia impairs sleep-dependent memory consolidation and may be ameliorated by eszopiclone. Larger samples may be needed to detect a significant effect on memory. Given the general role of sleep spindles in cognition, they offer a promising novel potential target for treating cognitive deficits in schizophrenia.
RCT Entities:
STUDY OBJECTIVES: In schizophrenia there is a dramatic reduction of sleep spindles that predicts deficient sleep-dependent memory consolidation. Eszopiclone (Lunesta), a non-benzodiazepine hypnotic, acts on γ-aminobutyric acid (GABA) neurons in the thalamic reticular nucleus where spindles are generated. We investigated whether eszopiclone could increase spindles and thereby improve memory consolidation in schizophrenia. DESIGN: In a double-blind design, patients were randomly assigned to receive either placebo or 3 mg of eszopiclone. Patients completed Baseline and Treatment visits, each consisting of two consecutive nights of polysomnography. On the second night of each visit, patients were trained on the motor sequence task (MST) at bedtime and tested the following morning. SETTING: Academic research center. PARTICIPANTS: Twenty-one chronic, medicated schizophrenia outpatients. MEASUREMENTS AND RESULTS: We compared the effects of two nights of eszopiclone vs. placebo on stage 2 sleep spindles and overnight changes in MST performance. Eszopiclone increased the number and density of spindles over baseline levels significantly more than placebo, but did not significantly enhance overnight MST improvement. In the combined eszopiclone and placebo groups, spindle number and density predicted overnight MST improvement. CONCLUSION:Eszopiclone significantly increased sleep spindles, which correlated with overnight motor sequence task improvement. These findings provide partial support for the hypothesis that the spindle deficit in schizophrenia impairs sleep-dependent memory consolidation and may be ameliorated by eszopiclone. Larger samples may be needed to detect a significant effect on memory. Given the general role of sleep spindles in cognition, they offer a promising novel potential target for treating cognitive deficits in schizophrenia.
Authors: A Karni; G Meyer; C Rey-Hipolito; P Jezzard; M M Adams; R Turner; L G Ungerleider Journal: Proc Natl Acad Sci U S A Date: 1998-02-03 Impact factor: 11.205
Authors: Matthew P Walker; Tiffany Brakefield; Joshua Seidman; Alexandra Morgan; J Allan Hobson; Robert Stickgold Journal: Learn Mem Date: 2003 Jul-Aug Impact factor: 2.460
Authors: M Schabus; T T Dang-Vu; G Albouy; E Balteau; M Boly; J Carrier; A Darsaud; C Degueldre; M Desseilles; S Gais; C Phillips; G Rauchs; C Schnakers; V Sterpenich; G Vandewalle; A Luxen; P Maquet Journal: Proc Natl Acad Sci U S A Date: 2007-08-01 Impact factor: 11.205
Authors: Elizabeth A Klingaman; Jessica Palmer-Bacon; Melanie E Bennett; Laura M Rowland Journal: Curr Psychiatry Rep Date: 2015-10 Impact factor: 5.285
Authors: Bengi Baran; David Correll; Tessa C Vuper; Alexandra Morgan; Simon J Durrant; Dara S Manoach; Robert Stickgold Journal: Schizophr Res Date: 2018-04-26 Impact factor: 4.939
Authors: David S Uygun; Fumi Katsuki; Yunren Bolortuya; David D Aguilar; James T McKenna; Stephen Thankachan; Robert W McCarley; Radhika Basheer; Ritchie E Brown; Robert E Strecker; James M McNally Journal: Sleep Date: 2019-02-01 Impact factor: 5.849